Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: multidrug resistance protein bispecific antibodies - Kenjockety Biotechnology

Next Previous
Drug Profile

Research programme: multidrug resistance protein bispecific antibodies - Kenjockety Biotechnology

Alternative Names: ABCC1 TAA BsAbs; MDR TAA BsAbs

Latest Information Update: 02 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kenjockety Biotechnology
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Multidrug resistance-associated protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Haematological malignancies; Solid tumours

Most Recent Events

  • 01 Dec 2021 Multidrug resistance protein bispecific antibodies are available for licensing as of 01 Dec 2021 (https://kenjocketybio.com/development#pipeline)
  • 25 Nov 2021 Early research in Haematological malignancies in USA (unspecified route) prior to November 2021 (Kenjockety Biotechnology pipeline, November 2021)
  • 25 Nov 2021 Early research in Solid tumours in USA (unspecified route) prior to November 2021 (Kenjockety Biotechnology pipeline, November 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top